IFFIm update

The International Finance Facility for Immunisation

René Karsenti, Chair IFFIm Board of Directors
1. Funding Gavi

2. IFFIm’s continued strategic role

3. Replicating IFFIm for Global Goals
Funding Gavi

- 2006 through March 2016: IFFIm has funded US$ 2.5 billion
- Represents 28% of total Gavi funding
- 2016-20: US$ 1.3 billion expected proceeds from IFFIm to Gavi including estimated proceeds from new pledges
- Australia has signed their pledge agreement: A$ 37.5 million 2016-2020
- The next capital markets transaction will be before the end of 2016

GAVI disbursement of IFFIm funds 2006 through 31-03-16

<table>
<thead>
<tr>
<th>Programme</th>
<th>Amount</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pentavalent vaccine</td>
<td>1,286,294,043</td>
<td>51.20%</td>
</tr>
<tr>
<td>Health System Strengthening (HSS)</td>
<td>281,084,309</td>
<td>11.20%</td>
</tr>
<tr>
<td>Pneumococcal vaccine</td>
<td>196,529,834</td>
<td>7.80%</td>
</tr>
<tr>
<td>Polio eradication</td>
<td>191,280,000</td>
<td>7.60%</td>
</tr>
<tr>
<td>Measles mortality reduction</td>
<td>139,000,000</td>
<td>5.50%</td>
</tr>
<tr>
<td>Yellow fever stockpiles</td>
<td>90,923,141</td>
<td>3.60%</td>
</tr>
<tr>
<td>Other country-specific programmes</td>
<td>83,339,830</td>
<td>3.30%</td>
</tr>
<tr>
<td>Meningitis elimination</td>
<td>62,609,996</td>
<td>2.50%</td>
</tr>
<tr>
<td>Maternal and neonatal tetanus</td>
<td>61,426,851</td>
<td>2.40%</td>
</tr>
<tr>
<td>Tetravalent vaccine</td>
<td>45,365,764</td>
<td>1.80%</td>
</tr>
<tr>
<td>Yellow fever vaccine</td>
<td>38,297,103</td>
<td>1.50%</td>
</tr>
<tr>
<td>Rotavirus vaccine</td>
<td>16,619,222</td>
<td>0.70%</td>
</tr>
<tr>
<td>Hepatitis B vaccine</td>
<td>13,116,872</td>
<td>0.50%</td>
</tr>
<tr>
<td>Measles vaccine</td>
<td>3,093,595</td>
<td>0.10%</td>
</tr>
<tr>
<td>Measles-Rubella vaccine</td>
<td>3,622,490</td>
<td>0.10%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2,512,603,051</strong></td>
<td><strong>100.00%</strong></td>
</tr>
</tbody>
</table>
Discussion among IFFIm donors, IFFIm Board and Gavi Secretariat about how to leverage IFFIm to help achieve Gavi’s goals

- **Vaccine scale-up**
  - To be coordinated with and support Gavi’s upcoming VIS process

- **Medium and long-term purchase guarantees**
  - How can IFFIm more directly support Gavi’s market shaping and procurement activities?

- **Cold Chain Equipment Optimization Platform**
  - Funding support and catalysing additional funding sources

- **Financing instrument for infectious disease outbreak response**
  - Exploring stand-by capital raising ability should Gavi decide to play a broader role in outbreak response
Donors confirmed a key objective of IFFIm is to deliver the best value for money

Vaccine scale-up:
- Overall support for this role: to be reviewed in 2018 in conjunction with VIS

Medium and long-term purchase guarantees
- Interest expressed by donors: continue analysis on legal, implementation and regulatory implications

Cold Chain Equipment Optimization Platform
- Continue analysis and incorporate outcomes of Gavi Board discussions
Donors confirmed a key objective of IFFIm is to deliver the best value for money

Financing instrument for infectious disease outbreak response
- IFFIm provides flexibility which can be leveraged in an outbreak situation like Ebola
- Continue analysis in coordination with Gavi’s overall processes in this area

Swaps and foreign exchange exposure
Examples of potential applications

- Contingent pledges as a financing tool for a Gavi outbreak response if the Gavi Board decides to play a role with a given vaccine
  - Pledges on “standby” to be activated upon an outbreak event
  - Objective is to raise capital rapidly and at scale
  - To be developed in collaboration with other complementary financing tools in the global community

- Financial guarantees to support Gavi market shaping
  - IFFIm’s balance sheet and credit strength will add to Gavi’s financial toolkit

- If approved by the Board, aspects of both applications could potentially be utilised to incentivise vaccine production for late-stage vaccine candidates or listed vaccines
Replicating IFFIm for Global Goals

- Demand for innovative finance and “surge funding” is growing

- Potential replication of the IFFIm model to meet Global Goals
  - Action Agenda of the Financing Development Conference
  - Resolution of the Political Declaration on HIV-AIDS

- Directors, in their personal capacities, are exploring possible International Finance Facilities (IFFs)

- Approached by the Sanitation and Hygiene sector

- Discussions with the education sector and climate change impact
Thank you

“Surge funding has been used often to finance immunization campaigns. The International Finance Facility for Immunization (IFFIm), which borrows against future government contributions to immunization programs, has raised billions of dollars over the past several years to ensure that vaccination campaigns are successful as soon as possible. In the long run, this is more effective than spending the same amount of money in yearly installments. IFFIm provides a convincing precedent for the current crisis.” George Soros, The Case for Surge Funding, Project Syndicate, February 17, 2016